Announcement on the Change of Investor Hotline
Filed with SSE · · 1 page · Chinese
Earlier from Sinotherapeutics
- Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets
- Announcement on Changes in Some Directors, Senior Management Members, Financial Chief and Core Technical Personnel
- Announcement on Canceling the Board of Supervisors and Amending the Articles of Association and Some Management Systems
- Announcement on Pledge Release of Some Shares Held by Shareholders with Over 5% Shares
- Announcement on Expiration of Plan of Shareholding Reduction by Shareholder with Over 5% Shares and Results of Shareholding Reduction
Later from Sinotherapeutics
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Implementation of Dividend Distribution for 2024
- Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Enzalutamide Tablets
- Announcement on Voluntary Disclosure of Obtaining EU GMP Certification by the Wholly-owned Subsidiary
- Announcement on Using Partial Idle Raised Funds for Cash Management
Follow Sinotherapeutics into a list and get an email when it puts out news.
Follow Sinotherapeutics